Profit rose to Rs 5,915 crore in the three months to March. Macquarie estimates headroom of about 1.4 per cent in the bank which will open up for buying. The stock ended up 1.11per centat Rs 209.50 on Wednesday.HSBC has maintained ‘buy’ rating on Aurobindo Pharma and cut target price to Rs 660 from Rs 715. The bank had registered a net loss of Rs 646.66 crore in the same quarter of previous fiscal. Its total income rose to Rs 5,814.42 crore during the fourth quarter of 2017-18 from Rs 5,661.70 crore in same period a year-ago.

Source: Economic Times May 31, 2018 02:44 UTC